Does DABRAFENIB Cause Product use in unapproved indication? 504 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 504 reports of Product use in unapproved indication have been filed in association with DABRAFENIB (Tafinlar). This represents 2.6% of all adverse event reports for DABRAFENIB.
504
Reports of Product use in unapproved indication with DABRAFENIB
2.6%
of all DABRAFENIB reports
94
Deaths
60
Hospitalizations
How Dangerous Is Product use in unapproved indication From DABRAFENIB?
Of the 504 reports, 94 (18.7%) resulted in death, 60 (11.9%) required hospitalization, and 4 (0.8%) were considered life-threatening.
Is Product use in unapproved indication Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for DABRAFENIB. However, 504 reports have been filed with the FAERS database.
What Other Side Effects Does DABRAFENIB Cause?
Pyrexia (3,788)
Death (2,740)
Malignant neoplasm progression (1,667)
Fatigue (1,328)
Nausea (1,300)
Chills (1,235)
Rash (1,078)
Vomiting (907)
Diarrhoea (901)
Headache (697)
What Other Drugs Cause Product use in unapproved indication?
DUPILUMAB (33,452)
DICLOFENAC (12,197)
METHOTREXATE (8,930)
PREDNISONE (7,625)
RITUXIMAB (7,519)
MYCOPHENOLATE MOFETIL (5,910)
ACETAMINOPHEN (5,819)
CYCLOPHOSPHAMIDE (5,750)
RISPERIDONE (5,551)
TACROLIMUS (5,057)
Which DABRAFENIB Alternatives Have Lower Product use in unapproved indication Risk?
DABRAFENIB vs DABRAFENIB\TRAMETINIB
DABRAFENIB vs DACARBAZINE
DABRAFENIB vs DACLATASVIR
DABRAFENIB vs DACLIZUMAB
DABRAFENIB vs DACOMITINIB